FibroBiologics CSO receives 61,607 stock options
FibroBiologics, Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
FibroBiologics, Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share. All 61,607 options are held directly and vest over four years, with one quarter vesting after one year and the remainder vesting monthly thereafter, contingent on continuous service.
Insider Trade Summary
Grant/Award: 61,607 shares
Grant/Award
1 txn
Insider
Khoja Hamid
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 61,607 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 61,607 contracts (Direct)
Footnotes (1)
- F1. On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods
Key Figures
Options granted: 61,607 options
Exercise price: $1.38 per share
Post-grant option holdings: 61,607 options
+3 more
6 metrics
Options granted
61,607 options
Stock Option (Right to Buy) grant on May 4, 2026
Exercise price
$1.38 per share
Conversion or exercise price for common stock underlying options
Post-grant option holdings
61,607 options
Total derivative securities following the grant, held directly
Expiration date
May 4, 2036
Option expiration for the granted stock options
Initial vesting
25% after 1 year
One fourth of option shares vest on first anniversary of grant date
Remaining vesting period
36 monthly installments
Balance vests monthly after first year, contingent on continuous service
Key Terms
Stock Option (Right to Buy), exercise price, vesting, continuous service
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.3800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"option shares shall vest on the one-year anniversary of the grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"until fully vested so long as the reporting person remains in continuous service"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did FibroBiologics (FBLG) report for Hamid Khoja?
FibroBiologics reported that Chief Scientific Officer Hamid Khoja received a stock option grant for 61,607 shares. These options allow him to buy common stock at a fixed price in the future, subject to vesting based on continued service with the company.
How many FibroBiologics (FBLG) options were granted to the Chief Scientific Officer?
The Chief Scientific Officer received options for 61,607 shares of FibroBiologics common stock. This entire amount is reflected as holdings following the transaction, indicating the grant created a new option position for the executive in this filing.
What is the exercise price of Hamid Khoja’s FibroBiologics (FBLG) stock options?
The granted stock options have an exercise price of $1.38 per share. This means Khoja can buy FibroBiologics common stock at $1.38 once the options vest, regardless of the market price at that time.
How do the FibroBiologics (FBLG) options granted to Hamid Khoja vest over time?
One quarter of the 61,607 option shares vest on the one-year anniversary of the May 4, 2026 grant date. The remaining options then vest in 36 equal monthly installments, conditioned on Khoja remaining in continuous service with FibroBiologics.
When do Hamid Khoja’s FibroBiologics (FBLG) stock options expire?
The stock options granted to Hamid Khoja are scheduled to expire on May 4, 2036. If not exercised by that date, any unexercised vested options will lapse and no longer allow the purchase of FibroBiologics common stock.
Is Hamid Khoja’s FibroBiologics (FBLG) option grant a market purchase or compensation award?
The transaction is a compensation-related award, not an open-market purchase. The Form 4 classifies it as a grant or other acquisition of derivative securities, with a zero-dollar transaction price and a specified exercise price of $1.38 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
